Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903/AMC-080 trial

We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV in a phase 2 prospective multicenter trial. The primary endpoint was 100-day non-relapse mortality (NRM). Patients had an 8/8 HLA-matched related or at least a 7/8 HLA-matched unrelated don...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biol Blood Marrow Transplant
Main Authors: Ambinder, Richard F., Wu, Juan, Logan, Brent, Durand, Christine M., Shields, Ryan, Popat, Uday R., Little, Richard F., McMahon, Deborah K., Cyktor, Joshua, Mellors, John W., Ayala, Ernesto, Kaplan, Lawrence D., Noy, Ariela, Jones, Richard J., Howard, Alan, Forman, Stephen J., Porter, David, Arce-Lara, Carlos, Shaughnessy, Paul, Sproat, Lisa, Hashmi, Shahrukh K., Mendizabal, Adam M., Horowitz, Mary M., Navarro, Willis H., Alvarnas, Joseph C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6907401/
https://ncbi.nlm.nih.gov/pubmed/31279752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.06.033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados